Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASA: Trifluridine/Tipiracil plus Anlotinib for Recurrent/Metastatic Esophageal Squamous Cell Carcinoma
ChiCTR2500105510Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: progression-free survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilanlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500105510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105510.